CD31-Mimetic Stent Coating for Rapid Endothelialization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Medical devices, particularly heart valves and vascular devices, trigger a foreign body response leading to chronic inflammation, platelet activation, and vascular obstruction due to their non-biocompatibility, hindering their use in treating cardiovascular conditions.
Innovation Solution
A CD31-mimetic peptide coating is applied to medical devices to mimic the trans-homophilic interaction between endothelial cells, platelets, and leukocytes, promoting rapid endothelialization and reducing platelet activation, thereby enhancing biocompatibility and integration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If medical devices are implanted in cardiovascular systems, then they can treat severe cardiovascular conditions, but they trigger foreign body response leading to platelet activation, chronic inflammation, and vascular obstruction
Solution Approach 1:
The patent applies the intermediary principle by introducing a peptide coating that mimics CD31, a natural endothelial cell surface protein. This peptide acts as a mediator between the medical device surface and the biological environment, preventing direct recognition of the device as foreign while promoting endothelial cell adhesion and activation of protective pathways that inhibit platelet activation and inflammation
Solution Approach 2:
The patent applies parameter changes by modifying the surface chemical and physical properties of the medical device through peptide coating. The coating alters surface charge, hydrophobicity, and molecular recognition sites to match those of native endothelium, thereby changing how blood elements and immune cells interact with the device surface
2Ease of manufacture
If the surface of medical devices is made non-biocompatible, then manufacturing is simpler, but rapid endothelialization and integration are prevented
Solution Approach 1:
The patent applies preliminary action by pre-coating the medical device surface with the CD31-mimetic peptide before implantation. This preliminary modification prepares the surface to actively promote endothelial cell adhesion, proliferation, and differentiation, ensuring rapid endothelialization occurs immediately upon implantation without requiring complex post-implantation protocols
3Ease of operation
If platelet adhesion and aggregation are excessive at the implantation site, then blood flow obstruction (ischemia) occurs, but preventing this requires complex anti-platelet strategies
Solution Approach 1:
The patent applies the blessing in disguise principle by converting the harmful platelet adhesion response into a beneficial anti-thrombotic state. The CD31-mimetic peptide coating activates protective signaling pathways that not only reduce platelet activation but also promote the release of anti-thrombotic factors by endothelial cells, effectively transforming the foreign body response into a protective mechanism
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CD31-mimetic peptide coating reduces platelet adhesion and activation, minimizing inflammation and vascular obstruction, potentially eliminating the need for anti-platelet therapy and improving the integration and performance of medical devices.
Implementation Method 1
Under healthy conditions, the trans-homophilic CD31-CD31 interaction allows the recognition of the 'self' by endothelial cells, platelets, and leukocytes preventing their inappropriate activation
Implementation Method 2
Cortese et al (Stroke, February 2021) discloses that the immobilization of a CD31-mimetic peptide P8RI (kwpalfvr) reduces the blood element reaction, increases the adhesion of endothelial cells in vitro and enhances the integration of endovascular devices in vivo
Data Source
AI summary
Inventors have synthesized peptides allowing an engagement of intact CD31 molecules on all the healthy endothelial cells and resting blood platelets and leukocytes that can enter in contact with an implanted device. Those cells can therefore receive the “leave-me-alone” signal delivered by the trans-homophilic engagement of CD31, which is essential to maintain the homeostasis in the circulation and vascularized tissues. Thrombotic or life-threatening occurrence of hemorrhagic or thromboembolic complications have impaired the use of endovascular devices. The devices bearing the mimicking peptides of the present invention are rapidly integrated, because they are perceived by blood platelets and leukocytes as a healthy endothelium, a “self” component. Furthermore, their ability to be rapidly endothelialized with a physiologic endothelial cell phenotype also limits platelet and leukocyte activation at the site of device implantation in the long-term. Accordingly, the present invention relates to peptides mimicking the trans-homophilic CD31-CD31 domain 1 and 2 intercellular interaction.